Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 735-740

  Jung, Seung Won ^a   Lee, So Young ^a   Jekarl, Dong Wook ^a   Kim, Myungshin ^a   Lim, Jihyang ^a   Kim, Yonggoo ^a   Han, Kyungja ^a   Kim, Yoo Jin ^a   Cho, Seok Goo ^a   Song, Juhee ^b  

^a The Catholic University of Korea   (South Korea)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Cytogenetics; Myelodysplastic syndrome; Prognosis

Indexed keywords

ACUTE LEUKEMIA; ADULT; AGED; AGING; ARTICLE; CANCER INCIDENCE; CHROMOSOME 5Q; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCORING SYSTEM; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79955636560     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.009     Document Type: Article

References (19)

1. Kouides P.A., Bennett J.M. Understanding myelodysplastic syndromes. Oncologist 1997, 2:389-401.
2. Bernasconi P., Boni M., Cavigliano P.M., Calatroni S., Giardini I., Rocca B., et al. Clinical relevance of cytogenetics in myelodysplastic Syndromes. Ann NY Acad Sci 2006, 1089:395-410.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in Myelodysplastic syndromes. Blood 1997, 89:2079-2088.
4. Pfeilstöcker M., Reisner R., Nösslinger T., Grüner H., Nowotny H., Tüchler H., et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999, 106:455-463.
5. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
6. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005, 19:767-775.
7. Lee J.H., Shin Y.R., Lee J.S., Kim W.K., Chi H.S., Park C.J., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003, 17:305-313.
8. Oguma S., Yoshida Y., Uchino H., Maekawa T., Nomura T., Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res 1995, 19:219-225.
9. ISCN, 2005: an international system for human cytogenetic nomenclature 2005, Karger, Basel. 1st ed. L.G. Shaffer, N. Tommerup (Eds.).
10. Mathew P., Tefferi A., Dewald G.W., Goldberg S.L., Su J., Hoagland H.C., et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993, 81:1040-1045.
11. Park M.J., Kim H., Kim S., Kim D.H., Kim S.J., Jang J.H., et al. Is international prognostic scoring system (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO classification-based prognostic scoring system (WPSS) and comparison with IPSS. Eur J Haematol 2008, 81:364-373.
12. Wang H., Wang X., Xu X., Lin G. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. Ann Hematol 2010, 89:535-544.
13. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patient. Blood 2007, 110:4385-4395.
14. Haase D., Steidl C., Schanz J., Schabla R., Pfeilstöcker M., Nösslinger T., et al. Correlation of cytogenetic findings with morphology, clinical courses and prognosis in 2124 patients with MDS. Blood 2005, 106:787-794.
15. Irons R.D., Lv L., Gross S.A., Ye X., Bao L., Wang X.Q., et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leuk Res 2006, 30:769-775.
16. Lee D.S., Kim S.H., Seo E.J., Park C.J., Chi H.S., Ko E.K., et al. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 2002, 132:97-101.
17. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
18. Matsuda A., Germing U., Jinnai I., Araseki K., Kuendgen A., Strupp C., et al. Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. Leuk Res 2010, 34:974-980.
19. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Giardini I., Rocca B., et al. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann Hematol 2010, 89:545-551.